Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 20/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 12/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 12/20 | 0.53 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29573844 | 0.84 | ADORA3 (0.64) | ADORA3ADORA1ADORA2ATMIGD3HTR2B | |
| SCHEMBL29573281 | 0.84 | ADORA3 (0.40) | ADORA3ADORA1ADORA2ATMIGD3HTR2B | |
| SCHEMBL29573550 | 0.82 | ADORA3 (0.74) | ADORA3ADORA1ADORA2A | |
| SCHEMBL29574004 | 0.81 | ADORA3 (0.69) | ADORA3ADORA1ADORA2ATMIGD3HTR2B | |
| SCHEMBL29574509 | 0.80 | ADORA3 (0.52) | ADORA3ADORA1TMIGD3HTR2B | |
| SCHEMBL29574325 | 0.74 | ADORA3 (0.61) | ADORA3ADORA1ADORA2ATMIGD3HTR2B | |
| SCHEMBL29574782 | 0.73 | ADORA3 (0.56) | ADORA3ADORA1ADORA2ATMIGD3HTR2B | |
| SCHEMBL29574294 | 0.73 | ADORA3 (0.52) | ADORA3ADORA1ADORA2ATMIGD3HTR2B | |
| SCHEMBL29573934 | 0.72 | ADORA3 (0.62) | ADORA3ADORA1ADORA2A | |
| SCHEMBL12805062 | 0.72 | ADORA3 (1.00) | ADORA3ADORA1ADORA2ATMIGD3HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4196219-A1 | A3 ADENOSINE RECEPTOR AGONISTS FOR USE IN MEDICINE | Biointervene, Inc. (US) | 2023-06-21 | — | — | EP | disclosed |
| WO-2022040241-A1 | A3 ADENOSINE RECEPTOR AGONISTS FOR USE IN MEDICINE | BIOINTERVENE, INC. (US) | 2022-02-24 | — | — | WO | disclosed |